Home Other Navigation Pharmacy + Providers Pharmacy Credentialing Important information Updated Insurance Coverage Information To submit a renewal, submit your updated certificate of insurance to...

Effective Date: July 1, 2026 Introduction, scope, and purpose: Prime Therapeutics LLC and all of its operating units and subsidiaries (“Prime,” “we,” “our”) understands that the privacy of your...

Prime Therapeutics experts share insights about the classification, cost and impact of these revolutionary drugs

These new solutions reflect Prime's distinctive conflict-free approach to the prescription drug supply chain model.

Home Newsroom Custom Content Publications High Cost Therapy Profile 2024-2025 High-Cost Therapy Profile: September 2024 Oncology/ cellular therapy Obecabtagene autoleucel Intravenous (IV) Autolus...

Pharmacy Friends In the latest episode of the “Pharmacy Friends” podcast, learn the latest insights on legislative trends, cutting-edge drug therapies and more from the 22nd annual event Alex Cook...

A female-presenting person speaks at a legislative building, wearing a green blazer and glasses. George Van Antwerp breaks down how Prime is poised to drive affordability in drug pricing Alex Cook...

Upgrade provides streamlined patient support and enhanced digital engagement for data-driven, holistic care

New Biosimilars First Generic Drug Launches Oct. 25, 2024 - sulopenem etzadroxil and probenecid (Orlynvah) The FDA has approved Iterum’s Orlynvah for the treatment of uncomplicated urinary tract...

Read Part 1 – Payer Survey Dive into Part 1 Hear from Prime’s medical pharmacy experts as they dive into the history of the report and offer their insights. Check out the events below to stay...